Global pharmaceutical firm Lotus Pharmaceutical (美時) announced its November revenue of NT$1.059 billion, consistent with the previous year. Cumulative revenue for the first 11 months reached NT$18.059 billion, up 5% YoY.

Market Resilience:

• Asia Business: Revenue grew 14% YoY, fueled by strong performance in Thailand and Vietnam (Southeast Asian revenue surged 115%). Mature markets like Taiwan and South Korea demonstrated resilience with single-digit growth, despite a 7% depreciation of the Korean Won against the New Taiwan Dollar.
• Export Markets: Export revenue saw a slight 3% decline. While the blood cancer drug Lenalidomide maintained double-digit growth in the U.S., it was offset by a decline in other export products and a 3% appreciation of the NTD against the USD.

Resource: 美時11月營收亞洲業務漲逾一成　台韓市場匯率壓抑下仍展現韌性